CONCORDBIO Stock Overview
A biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
CONCORDBIO passed our risk checks.
My Notes
Capture your thoughts, links and company narrative
Concord Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,129.35 |
| 52 Week High | ₹2,664.00 |
| 52 Week Low | ₹1,327.05 |
| Beta | 0 |
| 1 Month Change | 6.94% |
| 3 Month Change | -18.14% |
| 1 Year Change | 41.51% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 125.85% |
Recent News & Updates
Recent updates
Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 14
Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Sep 15Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing
Jul 23Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?
Feb 14Shareholder Returns
| CONCORDBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.9% | 0.8% | -4.2% |
| 1Y | 41.5% | 39.7% | 19.1% |
Return vs Industry: CONCORDBIO exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: CONCORDBIO exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| CONCORDBIO volatility | |
|---|---|
| CONCORDBIO Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: CONCORDBIO has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: CONCORDBIO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,377 | Sudhir Vaid | www.concordbiotech.com |
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications.
Concord Biotech Limited Fundamentals Summary
| CONCORDBIO fundamental statistics | |
|---|---|
| Market cap | ₹222.76b |
| Earnings (TTM) | ₹3.28b |
| Revenue (TTM) | ₹10.86b |
67.9x
P/E Ratio20.5x
P/S RatioIs CONCORDBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CONCORDBIO income statement (TTM) | |
|---|---|
| Revenue | ₹10.86b |
| Cost of Revenue | ₹2.76b |
| Gross Profit | ₹8.10b |
| Other Expenses | ₹4.82b |
| Earnings | ₹3.28b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 31.35 |
| Gross Margin | 74.57% |
| Net Profit Margin | 30.20% |
| Debt/Equity Ratio | 0% |
How did CONCORDBIO perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield30%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Concord Biotech Limited is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Deepika Murarka | Choice Equity Broking Private Limited |